Company ·
MetaVia holds a peptide molecule tracked on the Peptide Exchange board.
MetaVia has 1 molecule on the board and 1 news move logged. Each card shows the molecule's class, mechanism and current stage; open it for the full stage history.
Holdings
Incretins
Oxyntomodulin analog; GLP-1 and glucagon receptor dual agonist with a 3:1 GLP1R to GCGR potency ratio
MetaVia's weekly oxyntomodulin analog acts on GLP-1 and glucagon receptors. An interim Phase 1 Part 3B analysis showed 13.5% placebo-adjusted weight loss and a 68% placebo-adjusted cut in liver fat at Day 109, by the company's account.
Log
MetaVia will present a poster on DA-1726, its weekly GLP-1 and glucagon dual agonist, at ObesityWeek 2026 in Washington DC. The release names no new data, so the molecule joins our board at Phase 1 with a flat signal.
Holds P1